Are you over 18 and want to see adult content?
More Annotations
Create your own photography website : 30 day free trial - Photium
Are you over 18 and want to see adult content?
Blackpool Pleasure Beach: UK's Most ICONic Theme Park
Are you over 18 and want to see adult content?
Valentines 232 SW Ankeny St Portland Oregon
Are you over 18 and want to see adult content?
Компания по регистрации фирм в офшорных зонах, европейских странах и РФ и другие услуги для бизнеса - Прифинанс.
Are you over 18 and want to see adult content?
Craft-O-Maniac - Feeding The Creative Addiction!
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of xalxalmektebi.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of thebellyguide.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of blogdoshinhents.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of yaoihime.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of czechgaysolarium.com
Are you over 18 and want to see adult content?
A complete backup of zapinterlations.com
Are you over 18 and want to see adult content?
A complete backup of bigoliveapkmod.com
Are you over 18 and want to see adult content?
A complete backup of queenletiziastyle.com
Are you over 18 and want to see adult content?
Text
TERMS OF USE
Target the gene, silence the disease. The information provided on the Arrowhead Pharmaceuticals, Inc. Web Site is for general informationaland educational use
EVENTS & PRESENTATIONS 1 day ago · Title: ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Authors: Edward Gane, et al. Type: Late-Breaking Poster Date and Time: June 23, 2021 at 8:00 CEST. Title: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and ARROWHEAD ANNOUNCES IMPROVEMENT IN FIBROSIS AFTER ARO-AAT Target the gene, silence the disease. PASADENA, Calif.--(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed ARROWHEAD BEGINS PHASE 1 TRIAL OF ARC-AAT FOR TREATMENT OF PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has initiated dosing in a Phase 1 clinical trial of ARC-AAT, the company's candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder that severely ALNYLAM AND ARROWHEAD FORM COLLABORATION AND LICENSING Alnylam and Arrowhead Form Collaboration and Licensing Agreement – Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) – – Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate (DPC) Delivery Technology for ARROWHEAD RESEARCH CORPORATION ACQUIRES ROCHE RNA ASSETS Arrowhead Research Corporation Acquires Roche RNA Assets and Site Three New Delivery Technologies, Broad RNAi IP, and Advanced Operations to Drive Clinical Development, Partnerships, and Revenue Roche Takes Equity Stake in Arrowhead and Rights to Negotiate Future RNAi Candidates Conference Call Scheduled for Today at 4:30 PM ET ARROWHEAD RESEARCH PUBLISHES WHITE PAPER ON RNAI DELIVERY Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from RochePASADENA, Calif. — November 7, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview of its proprietary dynamic ARROWHEAD PHARMACEUTICALS, INC.PIPELINEABOUTSCIENCENEWS AND EVENTSINVESTORSCAREERS Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Learn More. CAREERS – ARROWHEAD PHARMACEUTICALS, INC.SCIENCEPRESS RELEASESOWNERSHIP PROFILESEC FILINGSCORPORATE GOVERNANCEINVESTOR FAQS Careers. Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deepand
OVERVIEW | ARROWHEAD PHARMACEUTICALS INC. Overview. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. ARROWHEAD PHARMACEUTICALS INITIATES DOSING PHASE 1/2 STUDY PASADENA, Calif.--(BUSINESS WIRE)--Aug. 11, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), which is a rare disease caused by EVENTS & PRESENTATIONS Event Details. May 18, 2021 11:30 AM EDT. 2021 RBC Capital Markets Global Healthcare. Listen to webcast. View Additional Information. Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation. May 4, 2021 4:30 PM EDT. Arrowhead Pharmaceuticals 2021 Second Quarter Results. Listen towebcast.
ARROWHEAD ANNOUNCES ARO-DUX4 AS FIRST MUSCLE TARGETED RNAI PASADENA, Calif.--(BUSINESS WIRE)--Apr. 15, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM) platform.ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential ARROWHEAD ANNOUNCES IMPROVEMENT IN FIBROSIS AFTER ARO-AAT Target the gene, silence the disease. PASADENA, Calif.--(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed ARROWHEAD PHARMACEUTICALS FILES IND FOR PHASE 2B STUDY OF PASADENA, Calif.--(BUSINESS WIRE)--Jan. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for 2021 VIRTUAL ALPHA-1 NATIONAL CONFERENCE The Investor Relations website contains information about Arrowhead Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts. UBS GLOBAL HEALTHCARE VIRTUAL CONFERENCE May 26, 2021 3:00 PM EDT. Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation.Listen to webcast.
ARROWHEAD PHARMACEUTICALS, INC.PIPELINEABOUTSCIENCENEWS AND EVENTSINVESTORSCAREERS Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Learn More. CAREERS – ARROWHEAD PHARMACEUTICALS, INC.SCIENCEPRESS RELEASESOWNERSHIP PROFILESEC FILINGSCORPORATE GOVERNANCEINVESTOR FAQS Careers. Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deepand
OVERVIEW | ARROWHEAD PHARMACEUTICALS INC. Overview. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. ARROWHEAD PHARMACEUTICALS INITIATES DOSING PHASE 1/2 STUDY PASADENA, Calif.--(BUSINESS WIRE)--Aug. 11, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), which is a rare disease caused by EVENTS & PRESENTATIONS Event Details. May 18, 2021 11:30 AM EDT. 2021 RBC Capital Markets Global Healthcare. Listen to webcast. View Additional Information. Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation. May 4, 2021 4:30 PM EDT. Arrowhead Pharmaceuticals 2021 Second Quarter Results. Listen towebcast.
ARROWHEAD ANNOUNCES ARO-DUX4 AS FIRST MUSCLE TARGETED RNAI PASADENA, Calif.--(BUSINESS WIRE)--Apr. 15, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM) platform.ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential ARROWHEAD ANNOUNCES IMPROVEMENT IN FIBROSIS AFTER ARO-AAT Target the gene, silence the disease. PASADENA, Calif.--(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed ARROWHEAD PHARMACEUTICALS FILES IND FOR PHASE 2B STUDY OF PASADENA, Calif.--(BUSINESS WIRE)--Jan. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for 2021 VIRTUAL ALPHA-1 NATIONAL CONFERENCE The Investor Relations website contains information about Arrowhead Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts. UBS GLOBAL HEALTHCARE VIRTUAL CONFERENCE May 26, 2021 3:00 PM EDT. Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation.Listen to webcast.
PIPELINE – ARROWHEAD PHARMACEUTICALS, INC. ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. Reducing production of the inflammatory Z-AAT protein is expected to halt the progression of liver disease and potentially allow it to regenerate and repair. Disease. ABOUT – ARROWHEAD PHARMACEUTICALS, INC. Overview. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. SCIENCE – ARROWHEAD PHARMACEUTICALS, INC. Targeted RNAi Molecule (TRiM TM) Platform. Arrowhead’s Targeted RNAi Molecule, or TRiM TM, platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple.Targeting has been core to Arrowhead’s development philosophy and the TRiM TM platform builds on more than a decade of work on actively targeted drug delivery vehicles.PRESS RELEASES
Press Releases. Conference Call and Webcast Today, May 4, 2021 at 4:30 p.m. ET PASADENA, Calif. -- (BUSINESS WIRE)--May 4, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2021 . The company is hosting a conference call today, May. PASADENA, Calif. -- (BUSINESS ARROWHEAD PHARMACEUTICALS INITIATES PHASE 2B STUDY OF Target the gene, silence the disease. PASADENA, Calif.--(BUSINESS WIRE)--Jun. 3, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe ARROWHEAD PHARMACEUTICALS FILES IND TO BEGIN PHASE 2B PASADENA, Calif.--(BUSINESS WIRE)--Mar. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with hypertriglyceridemia. ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1B STUDY OF ARO PASADENA, Calif.--(BUSINESS WIRE)--Aug. 18, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).TERMS OF USE
Target the gene, silence the disease. The information provided on the Arrowhead Pharmaceuticals, Inc. Web Site is for general informationaland educational use
ARROWHEAD RESEARCH PUBLISHES WHITE PAPER ON RNAI DELIVERY Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from RochePASADENA, Calif. — November 7, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview of its proprietary dynamic ARROWHEAD RESEARCH CORPORATION ACQUIRES ROCHE RNA ASSETS Arrowhead Research Corporation Acquires Roche RNA Assets and Site Three New Delivery Technologies, Broad RNAi IP, and Advanced Operations to Drive Clinical Development, Partnerships, and Revenue Roche Takes Equity Stake in Arrowhead and Rights to Negotiate Future RNAi Candidates Conference Call Scheduled for Today at 4:30 PM ET ARROWHEAD PHARMACEUTICALS, INC.PIPELINEABOUTSCIENCENEWS AND EVENTSINVESTORSCAREERS Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Learn More. ABOUT – ARROWHEAD PHARMACEUTICALS, INC. Overview. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. PIPELINE – ARROWHEAD PHARMACEUTICALS, INC. ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. Reducing production of the inflammatory Z-AAT protein is expected to halt the progression of liver disease and potentially allow it to regenerate and repair. Disease. CAREERS – ARROWHEAD PHARMACEUTICALS, INC. Careers. Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deepand
CONTACT – ARROWHEAD PHARMACEUTICALS, INC. Vince Anzalone, CFA Arrowhead Pharmaceuticals, Inc. Call: 626-304-3400 ir@arrowheadpharma.com. Brian Ritchie LifeSci Advisors Call: 212-915-2578 britchie@lifesciadvisors.com. OVERVIEW | ARROWHEAD PHARMACEUTICALS INC. Overview. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. ARROWHEAD PHARMACEUTICALS INITIATES DOSING PHASE 1/2 STUDY PASADENA, Calif.--(BUSINESS WIRE)--Aug. 11, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), which is a rare disease caused by ARROWHEAD ANNOUNCES ARO-DUX4 AS FIRST MUSCLE TARGETED RNAI PASADENA, Calif.--(BUSINESS WIRE)--Apr. 15, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM) platform.ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential ARROWHEAD ANNOUNCES IMPROVEMENT IN FIBROSIS AFTER ARO-AAT Target the gene, silence the disease. PASADENA, Calif.--(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed ARROWHEAD ENTERS $3.7 BILLION LICENSE AND COLLABORATION - Upon closing, Arrowhead to receive $250 million, consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc. - Arrowhead eligible to receive additional $3.5 billion in potential milestone payments, and potential further royalties on commercial sales ARROWHEAD PHARMACEUTICALS, INC.PIPELINEABOUTSCIENCENEWS AND EVENTSINVESTORSCAREERS Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Learn More. ABOUT – ARROWHEAD PHARMACEUTICALS, INC. Overview. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. PIPELINE – ARROWHEAD PHARMACEUTICALS, INC. ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. Reducing production of the inflammatory Z-AAT protein is expected to halt the progression of liver disease and potentially allow it to regenerate and repair. Disease. CAREERS – ARROWHEAD PHARMACEUTICALS, INC. Careers. Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deepand
CONTACT – ARROWHEAD PHARMACEUTICALS, INC. Vince Anzalone, CFA Arrowhead Pharmaceuticals, Inc. Call: 626-304-3400 ir@arrowheadpharma.com. Brian Ritchie LifeSci Advisors Call: 212-915-2578 britchie@lifesciadvisors.com. OVERVIEW | ARROWHEAD PHARMACEUTICALS INC. Overview. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. ARROWHEAD PHARMACEUTICALS INITIATES DOSING PHASE 1/2 STUDY PASADENA, Calif.--(BUSINESS WIRE)--Aug. 11, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), which is a rare disease caused by ARROWHEAD ANNOUNCES ARO-DUX4 AS FIRST MUSCLE TARGETED RNAI PASADENA, Calif.--(BUSINESS WIRE)--Apr. 15, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM) platform.ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential ARROWHEAD ANNOUNCES IMPROVEMENT IN FIBROSIS AFTER ARO-AAT Target the gene, silence the disease. PASADENA, Calif.--(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed ARROWHEAD ENTERS $3.7 BILLION LICENSE AND COLLABORATION - Upon closing, Arrowhead to receive $250 million, consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc. - Arrowhead eligible to receive additional $3.5 billion in potential milestone payments, and potential further royalties on commercial sales SCIENCE – ARROWHEAD PHARMACEUTICALS, INC. Targeted RNAi Molecule (TRiM TM) Platform. Arrowhead’s Targeted RNAi Molecule, or TRiM TM, platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple.Targeting has been core to Arrowhead’s development philosophy and the TRiM TM platform builds on more than a decade of work on actively targeted drug delivery vehicles. CONTACT – ARROWHEAD PHARMACEUTICALS, INC. Vince Anzalone, CFA Arrowhead Pharmaceuticals, Inc. Call: 626-304-3400 ir@arrowheadpharma.com. Brian Ritchie LifeSci Advisors Call: 212-915-2578 britchie@lifesciadvisors.com. EVENTS & PRESENTATIONS Event Details. May 18, 2021 11:30 AM EDT. 2021 RBC Capital Markets Global Healthcare. Listen to webcast. View Additional Information. Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation. May 4, 2021 4:30 PM EDT. Arrowhead Pharmaceuticals 2021 Second Quarter Results. Listen towebcast.
ARROWHEAD ANNOUNCES IMPROVEMENT IN FIBROSIS AFTER ARO-AAT Target the gene, silence the disease. PASADENA, Calif.--(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developedTERMS OF USE
Target the gene, silence the disease. The information provided on the Arrowhead Pharmaceuticals, Inc. Web Site is for general informationaland educational use
ARROWHEAD PHARMACEUTICALS FILES IND FOR PHASE 2B STUDY OF PASADENA, Calif.--(BUSINESS WIRE)--Jan. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for UBS GLOBAL HEALTHCARE VIRTUAL CONFERENCE May 26, 2021 3:00 PM EDT. Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation.Listen to webcast.
ARROWHEAD PHARMACEUTICALS PRESENTS ARC-AAT CLINICAL DATA PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) presented clinical data from a Phase 1a/1b study of ARC-AAT, the company's prior generation investigational medicine that was being studied for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), at The International Liver Congress™ 2017 (ILC), the annual meeting of ARROWHEAD COMPLETES DOSING IN PHASE 1 STUDY OF ARO-AAT FOR PASADENA, Calif.--(BUSINESS WIRE)--Aug. 31, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin ARROWHEAD RESEARCH CORPORATION ACQUIRES ROCHE RNA ASSETS Arrowhead Research Corporation Acquires Roche RNA Assets and Site Three New Delivery Technologies, Broad RNAi IP, and Advanced Operations to Drive Clinical Development, Partnerships, and Revenue Roche Takes Equity Stake in Arrowhead and Rights to Negotiate Future RNAi Candidates Conference Call Scheduled for Today at 4:30 PM ETSkip to content
Arrowhead Pharmaceuticals, Inc.__
* About
* Overview
* Management
* Board of Directors * Scientific Advisors* Pipeline
* Overview
* ARO-AAT
* ARO-APOC3
* ARO-ANG3
* ARO-HSD
* ARO-ENaC
* ARO-Lung2
* ARO-COV
* ARO-HIF2
* JNJ-3989
* AMG 890
* ARO-JNJ1
* Science
* Overview
* Publications
* News and Events
* Investors
* Overview
* Press Releases
* Events & Presentations * Corporate Governance * Financials & Filings* SEC Filings
* Annual Reports
* Quarterly Results
* Key Ratios
* Stock Information
* Historic Stock Lookup* Stock Splits
* Analyst Coverage
* Ownership Profile
* Investor FAQs
* Contact Us
* Careers
* Contact
____ Search for: __
TARGET THE GENE
SILENCE THE DISEASE
May 7, 2020 - Arrowhead Pharmaceuticals Reports Fiscal 2020 SecondQuarter Results
View More »
Oct 18, 2019 8:00 AM EDT Arrowhead Analyst R&D Day 2019 ViewPIPELINE
Drug(Disease)
Disease
Pre-clinical
Pre-IND
Phase 1
Phase 2
Phase 3
*
ARO-AAT (Alpha-1 Liver Disease) Alpha-1 Liver Disease*
ARO-APOC3 (Hypertriglyceridemia) Hypertriglyceridemia*
ARO-ANG3 (Dyslipidemia)Dyslipidemia
*
ARO-HSD (Liver Disease)Liver Disease
*
ARO-ENaC (Cystic Fibrosis)Cystic Fibrosis
*
ARO-Lung2 (COPD)
COPD
*
ARO-COV (COVID-19 )
COVID-19
*
ARO-HIF2 (Renal Cell Carcinoma) Renal Cell Carcinoma*
JNJ-3989 (Hepatitis B)Hepatitis B
Licensed to Janssen
*
AMG 890 (Cardiovascular Disease) Cardiovascular DiseaseLicensed to Amgen
*
ARO-JNJ1 (Undisclosed)Undisclosed
Partnered with Janssen* Liver
* Lung
* Tumor
Learn More
SCIENCE
Arrowhead has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies.Learn More
ABOUT ARROWHEAD
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.Learn More
* Sitemap
* Privacy Policy
* Terms of Use
* Follow Us: __ __
Copyright © Arrowhead Pharmaceuticals, Inc. Website Design by MentusDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0